Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV
Infants of hepatitis B virus (HBV)-infected mothers with positive hepatitis B e antigen (HBeAg) have an increased risk of becoming infected with HBV. This study will determine whether telbivudine among both hepatitis B surface antigen (HBsAg) and HBeAg positive pregnant women during the third trimester, in addition to standard immunoprophylaxis in infants, will be more effective than standard immunoprophylaxis alone at preventing HBV infections in these infants.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Telbivudine in the Third Trimester of Pregnancy to Prevent Mother-to-infant Transmission of HBV|
- HBV serologic markers and alanine transaminase (ALT) levels in infants [ Time Frame: 10 months after birth ] [ Designated as safety issue: No ]HBsAg and HBeAg are tested in umbilical blood and peripheral blood collected at the age of 10 months respectively. ALT is measured at 10 months old.
- HBV DNA quantification and ALT levels in mothers [ Time Frame: Up to 10 months postpartum ] [ Designated as safety issue: No ]HBV DNA and ALT levels in the pregnant women are measured before taking telbivudine, at birth, 1-2 months after stopping the drug, and 10 months postpartum.
- Women and infants with adverse events [ Time Frame: Up to 10 months after delivery/birth ] [ Designated as safety issue: Yes ]Adverse events in pregnant women during pregnancy, complications at delivery and postpartum, Apgar score, newborn infant deformity, infant growth and development will be recorded during the study period (up to 10 months after delivery/birth).
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||October 2014|
|Estimated Primary Completion Date:||March 2014 (Final data collection date for primary outcome measure)|
HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
No Intervention: Control
Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
Infants of HBV-infected mothers with positive HBeAg have an increased risk of becoming infected with HBV. Standard immunoprophylaxis against mother-to-infant transmission of HBV includes administration of hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine; however, approximately 5-15% of the infants are not protected despite having received these preventive measures. It is reported that antiviral prophylaxis among HBV-infected pregnant women can reduce mother-to-infant transmission of HBV. However, more research is needed to obtain the definite conclusion. This study will determine whether telbivudine among HBsAg- and HBeAg-positive pregnant women during the third trimester, in addition to standard immunoprophylaxis in infants, will be more effective than standard immunoprophylaxis alone at preventing HBV infections in these infants.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01637844
|Contact: Yi-Hua Zhou, MD, PhD||+86 25 8330 4616 ext firstname.lastname@example.org|
|Contact: Yali Hu, MD, PhD||+86 25 8330 4616 ext email@example.com|
|Nanjing Drum Tower Hospital||Recruiting|
|Nanjing, Jiangsu, China, 210008|
|Contact: Yi-Hua Zhou, MD, PhD +86 25 8330 4616 ext 10373 firstname.lastname@example.org|
|Principal Investigator: Yi-Hua Zhou, MD, PhD|
|Principal Investigator: Yali Hu, MD, PhD|
|Taixing People's Hospital||Recruiting|
|Taixing, Jiangsu, China, 225400|
|Contact: Biao Xu, MD email@example.com|
|Principal Investigator: Biao Xu, MD|
|Zhenjiang Fourth People's Hospital||Recruiting|
|Zhenjiang, Jiangsu, China, 212001|
|Contact: Jian Wen, MD firstname.lastname@example.org|
|Principal Investigator: Jian Wen, MD|
|Study Director:||Yali Hu, MD, PhD||Nanjing Drum Tower Hospital, Nanjing University Medical School|